Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

RDN for CKD and Uncontrolled Hypertension Trial

16. November 2026 aktualisiert von: Beijing Anzhen Hospital

Effect and Safety of Renal Denervation in Uncontrolled Hypertension and Chronic Kidney Disease: A Randomized, Sham-control, Blinded, Clinical Trial

Prospective, Multi-Center, Randomized, Parallel-Controlled, Uptake clinical trial to evaluate the efficacy and safety of renal denervation in patients with uncontrolled hypertension and chronic kidney disease.

Studienübersicht

Detaillierte Beschreibung

This Prospective, Multi-Center, Randomized, parallel-controlled uptake clinical trial aims to evaluate the efficacy and safety for renal denervation in patients with uncontrolled hypertension and chronic kidney disease, and to provide clinical evidence supporting the expansion of indications.

Studientyp

Interventionell

Einschreibung (Geschätzt)

248

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

      • Beijing, China, 101118
        • Rekrutierung
        • Beijing Anzhen Hospital
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Male or female, aged 18 to 65 years, inclusive, at the time of consent;
  2. Hypertensive subjects who have been taking 2 types of standardized antihypertensive drugs continuously and stably for at least 4 weeks, with office systolic blood pressure still ≥150 mmHg and <180 mmHg, and 24-hour ambulatory mean systolic blood pressure (24h SBP) ≥135 mmHg and <170 mmHg; or who have been taking ≥3 types of standardized antihypertensive drugs continuously and stably for at least 4 weeks, with office systolic blood pressure ≥140 mmHg and <180 mmHg, and 24h SBP ≥130 mmHg and <170 mmHg;
  3. Estimated glomerular filtration rate (eGFR) ≥20 mL/min/1.73m² and <60 mL/min/1.73m²;
  4. The presence or absence of accessory renal arteries is acceptable;
  5. The subject or his/her legal representative fully understands the content of the informed consent form for this trial and voluntarily signs the written informed consent form.

Exclusion Criteria:

  1. Pregnant or breastfeeding, or planning pregnancy during the study.
  2. Renal artery anatomy unsuitable for ablation (e.g., ≥50% stenosis, renal artery aneurysm, malformation, renal artery diameter <3 mm, or treatable segment length <20 mm).
  3. Subjects with a solitary kidney, prior renal transplantation, or requiring dialysis.
  4. Prior renal artery intervention or prior renal denervation.
  5. Other secondary hypertension not related to kidney disease (such as primary aldosteronism, pheochromocytoma/paraganglioma, Cushing's syndrome, thyroid disease, aortic coarctation, monogenic hypertension, renovascular hypertension, etc.).
  6. Allergic to contrast agents.
  7. Major surgery or trauma within 1 month before enrollment; acute coronary syndrome within 6 months; or planned surgery or cardiovascular interventional therapy within the next 6 months.
  8. Orthostatic hypotension.
  9. Type 1 diabetes mellitus.
  10. Primary pulmonary arterial hypertension.
  11. History of bleeding diathesis and haematological disorders or coagulopathy
  12. History of thromboembolic event within 6 months.
  13. History of stroke or transient ischemic attack (TIA) within 6 months.
  14. Severe peripheral arterial disease or unstable abdominal aortic aneurysm.
  15. Severe valvular heart disease or anticipated need for surgical valve replacement during the study period.
  16. NYHA Class III/IV heart failure at screening or hospitalization for exacerbation of chronic heart failure within the past six months.
  17. History of ventricular fibrillation, polymorphic ventricular tachycardia within six months, or prior implantation of an implantable cardioverter-defibrillator (ICD) or pacemaker.
  18. Acute kidney injury (AKI) within 4 weeks before enrollment or acute kidney disease ,AKI: ≥50% increase in serum creatinine within 7 days, or absolute increase ≥0.3 mg/dL (≥26.5 μmol/L) within 48 hours, or oliguria (<0.5 mL·kg-¹·h-¹ for ≥6 hours).
  19. Severe hepatic dysfunction.
  20. Concomitant severe diseases that may interfere with study participation or affect survival, such as malignancy or AIDS.
  21. Known drug or alcohol dependence, difficulty understanding the study protocol, inability or unwillingness to comply with follow-up requirements.
  22. Current or planned participation in other clinical trials of drugs or medical devices (post-marketing registry studies permitted).
  23. Acute or severe systemic infection.
  24. Other conditions deemed unsuitable for participation by the investigator.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Renal Denervation (RDN)

Participants receive percutaneous renal sympathetic denervation under digital subtraction angiography (DSA) guidance using a ultra-guiding radiofrequency denervation catheter. All participants receive a standardized antihypertensive regimen for ≥4 weeks before the procedure and thereafter per protocol. Follow-up visits occur at 7 days or before discharge, and at 1, 3, 6, 12 months.

DSA-guided percutaneous renal sympathetic denervation using a RF renal denervation system

Andere Namen:
  • Nierendenervation
Schein-Komparator: Parallel control with sham operation

Participants undergo a sham procedure: femoral artery puncture and selective renal angiography under DSA guidance are performed. The RF generator is connected to a dummy load, and activation sounds are emitted, but no energy is delivered. Participants remain on the procedure table for at least 35 minutes before sheath removal. Background standardized antihypertensive therapy is provided for ≥4 weeks pre-procedure and continued per protocol. Follow-up visits occur at 7 days or before discharge, and at 1, 3, 6, and 12 months.

Sham procedure including femoral artery puncture and selective renal angiography; the radiofrequency generator is connected to a dummy load and produces activation sounds, but no energy is delivered. Minimum table time before sheath removal is 35 minutes.

Andere Namen:
  • Renale Angiographie

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change from Baseline in 24-hour Ambulatory Systolic Blood Pressure at Month 6 (ABPM)
Zeitfenster: Baseline to Month 6 post-procedure

24-hour mean systolic BP measured by validated ambulatory BP monitoring; change is Month 6 minus Baseline

Baseline to Month 6 post-procedure

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change from Baseline in 24-hour Ambulatory Diastolic Blood Pressure at Month 6 (ABPM)
Zeitfenster: Baseline to Month 6 post-procedure

24-hour mean systolic BP measured by validated ambulatory BP monitoring

Baseline to Month 6 post-procedure
Change from Baseline in Office Blood Pressure (including both systolic and diastolic BP)
Zeitfenster: Baseline to Months 1, 3, 6 and 12 post-procedure

measured by validated office blood pressure monitoring

Baseline to Months 1, 3, 6 and 12 post-procedure
Change from Baseline in 24-hour Ambulatory Systolic Blood Pressure (including both systolic and diastolic BP)
Zeitfenster: Baseline to Months 1, 3, and 12 post-procedure

24-hour mean systolic BP measured by validated ambulatory BP monitoring

Baseline to Months 1, 3, and 12 post-procedure
Change from Baseline in Daytime and Nighttime Ambulatory Systolic Blood Pressure (ABPM)
Zeitfenster: Baseline to Months 1, 3, 6, and 12 post-procedure

24-hour mean systolic BP measured in Daytime and Nighttime by validated ambulatory BP monitoring

Baseline to Months 1, 3, 6, and 12 post-procedure
Percentage of Participants with 24-hour Ambulatory Systolic BP <130 mmHg
Zeitfenster: Months 1, 3, 6, and 12 post-procedure

24-hour mean systolic BP measured by validated ambulatory BP monitoring

Months 1, 3, 6, and 12 post-procedure
Percentage of subjects with office systolic BP within the target ranges (<140 mmHg and <130 mmHg)
Zeitfenster: Months 6 and 12 post-procedure

measured by validated office blood pressure monitoring

Months 6 and 12 post-procedure
Responder Rate: ≥5 mmHg Reduction in office Systolic BP
Zeitfenster: Months 6 and 12 post-procedure

Proportion of participants with a reduction ≥5 mmHg from baseline in office BP

Months 6 and 12 post-procedure
Change from Baseline in Antihypertensive Medication Use
Zeitfenster: Months 1, 3, 6 and 12 post-procedure

Change in the number of concurrently prescribed antihypertensive agents

Months 1, 3, 6 and 12 post-procedure
Change from Baseline in serum creatinine levels
Zeitfenster: Months 1, 3, 6 and 12 post-procedure

Change in postoperative serum creatinine levels relative to baseline

Months 1, 3, 6 and 12 post-procedure
Changes from Baseline in glomerular filtration rate
Zeitfenster: Months 1, 3, 6 and 12 post-procedure

Changes in glomerular filtration rate relative to baseline

Months 1, 3, 6 and 12 post-procedure
Changes from Baseline in the urine microalbumin-to-creatinine ratio
Zeitfenster: Months 1, 3, 6 and 12 post-procedure

Changes in the urine microalbumin-to-creatinine ratio relative to baseline

Months 1, 3, 6 and 12 post-procedure
Change from Baseline in Heart Rate (by ECG)
Zeitfenster: Months 1, 3, 6 and 12 post-procedure

Resting heart rate measured by standard 12-lead ECG; change is Follow-up minus Baseline

Months 1, 3, 6 and 12 post-procedure
Change from Baseline in left ventricular ejection fraction (LVEF) (by Echocardiography)
Zeitfenster: Months 12 post-procedure

by Echocardiography

Months 12 post-procedure
Change from Baseline in left ventricular mass index
Zeitfenster: Months 12 post-procedure

by Echocardiography

Months 12 post-procedure

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

8. Dezember 2025

Primärer Abschluss (Geschätzt)

31. Oktober 2027

Studienabschluss (Geschätzt)

30. April 2028

Studienanmeldedaten

Zuerst eingereicht

26. Oktober 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

16. November 2026

Zuerst gepostet (Tatsächlich)

18. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

16. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren